Peringkat dalam Saham
#5977
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Kapitalisasi Pasar
$2.33B
Perubahan (1 hari)
11.43%
Perubahan (1 tahun)
408.10%
Perdagangan Nanobiotix S.A. (NANO)
Harga NANO dengan kapitalisasi pasar B
Kapitalisasi pasar dari Nanobiotix S.A.(NANO)
Kapitalisasi Pasar: $2.33B
Per August 2026, Nanobiotix S.A. memiliki kapitalisasi pasar sebesar $2.33B. Ini menjadikan Nanobiotix S.A. sebagai perusahaan 5977th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Nanobiotix S.A. dari 2012 hingga 2026
NANO dibandingkan dengan 5 teratas stocks paling populer
| Harga NANO |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.565T
|
+239,145.35%
|
|
|
|
|
$4.629T
|
+198,886.75%
|
|
|
|
|
$4.102T
|
+176,246.07%
|
|
|
|
|
$3.745T
|
+160,885.28%
|
|
|
|
|
$2.754T
|
+118,311.80%
|
